Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer...

Area of Science:

• Oncology
• Immunotherapy
• Biomaterials

Background:

• Recombinant oncolytic adenovirus shows promise for cancer treatment but has limited standalone efficacy.
• Bladder cancer requires novel therapeutic strategies to improve patient outcomes.

Purpose of the Study:

• To investigate the efficacy of combining recombinant oncolytic adenovirus-loaded silk hydrogel with a PD-L1 inhibitor for bladder cancer treatment.
• To evaluate the role of CRB3 in bladder cancer and its potential as a therapeutic target.

Main Methods:

• Single-cell sequencing of bladder cancer tissues to identify key genes.
• In vitro validation of CRB3's inhibitory role on cancer cell proliferation, migration, and invasion.
• Construction and in vivo evaluation of recombinant oncolytic adenoviruses encoding CRB3 and GM-CSF encapsulated in silk hydrogel.
• Combination therapy assessment with PD-L1 inhibitor in a mouse bladder cancer model.

Main Results:

• CRB3 was identified as a key gene suppressing bladder cancer cell growth and metastasis.
• The silk hydrogel nano-composite effectively delivered oncolytic adenoviruses, inhibiting tumor growth and increasing immune infiltration.
• Combination treatment significantly enhanced T-cell infiltration and tumor cell killing compared to monotherapy.

Conclusions:

• Co-administering oncolytic adenovirus silk hydrogel encoding CRB3 and GM-CSF with a PD-L1 inhibitor represents a potent therapeutic strategy for bladder cancer.
• This combination approach effectively recruits T cells to the tumor microenvironment, leading to improved anti-tumor immunity and treatment outcomes.
• The developed nano-composite hydrogel system offers a novel and efficient platform for delivering oncolytic viruses and therapeutic agents in cancer treatment.